Medications for Follicular Lymphoma
13 results
Aliqopa (copanlisib)
(copanlisib)Bayer HealthCare Pharmaceuticals Inc.
Usage: ALIQOPA is indicated for adult patients with relapsed follicular lymphoma (FL) who have undergone at least two prior systemic therapies. It received accelerated approval based on overall response rates, with continued approval dependent on confirmation of clinical benefits in further studies.
Breyanzi (lisocabtagene maraleucel)
(Lisocabtagene maraleucel)Juno Therapeutics, Inc.
Usage: BREYANZI is indicated for treating adult patients with relapsed or refractory large B-cell lymphoma (LBCL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma (FL), or mantle cell lymphoma (MCL) after multiple prior therapies, with specific restrictions on certain conditions.
Brukinsa (zanubrutinib)
(zanubrutinib)BEIGENE USA, INC.
Usage: BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma, Waldenström's macroglobulinemia, relapsed or refractory marginal zone lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed or refractory follicular lymphoma in combination with obinutuzumab, following prior therapies.
Epkinly (epcoritamab-bysp)
(epcoritamab-bysp)Genmab US, Inc.
Usage: EPKINLY is indicated for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma after two or more lines of systemic therapy. It is also approved for relapsed or refractory follicular lymphoma (FL) in similar circumstances. Continued approval may depend on confirmatory trials.
Gazyva (obinutuzumab)
(obinutuzumab)Genentech, Inc.
Usage: GAZYVA is indicated for treating previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil. It is also used for relapsed or refractory follicular lymphoma, in combination with bendamustine, and for previously untreated advanced follicular lymphoma, in combination with chemotherapy followed by GAZYVA monotherapy.
Kymriah (tisagenlecleucel)
(tisagenlecleucel)Novartis Pharmaceuticals Corporation
Usage: KYMRIAH is indicated for the treatment of pediatric and young adult patients (up to 25 years) with relapsed or refractory B-cell acute lymphoblastic leukemia, and adult patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma after two or more lines of systemic therapy.
Lenalidomide (lenalidomide)
(Lenalidomide)Biocon Pharma Inc.
Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.
Lenalidomide (lenalidomide)
(lenalidomide)Cipla USA Inc.
Usage: Lenalidomide capsules are indicated for treating adult patients with multiple myeloma (in combination with dexamethasone or as maintenance therapy post-transplant), myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma (with rituximab). Not recommended for chronic lymphocytic leukemia outside clinical trials.
Lunsumio (mosunetuzumab)
(Mosunetuzumab)Genentech, Inc.
Usage: LUNSUMIO is indicated for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Its approval is based on response rate and may require further confirmation of clinical benefit in ongoing trials.
Revlimid (lenalidomide)
(Lenalidomide)Celgene Corporation
Usage: REVLIMID is indicated for treating adult patients with multiple myeloma (in combination with dexamethasone), myelodysplastic syndromes associated with 5q deletion, relapsed mantle cell lymphoma, and previously treated follicular or marginal zone lymphoma (with rituximab). It is not recommended for chronic lymphocytic leukemia outside clinical trials.